Payment overview · 2025
General Payments
$1,912.65
79 reported records · 18 companies
Healthcare provider profile · identity verified
Ahmad Goodarzi, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · HOUSTON, TX · NPI 1992012173
Verified facts
What the public records show
CMS Open Payments records show Ahmad Goodarzi, M.D. received $1,912.65 in general payments during 2025 across 79 reported records.
Actelion Pharmaceuticals US, Inc. accounted for 15.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Cresemba, Ofev.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Cresemba as an associated drug or biological on 2800 records involving 1563 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Cresemba by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OFEV as an associated drug or biological on 14236 records involving 6873 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Ofev by this doctor in 2024.
Grifols USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Gamunex-C as an associated drug or biological on 3977 records involving 2134 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Gamunex-C by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PREVYMIS as an associated drug or biological on 2265 records involving 1245 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Prevymis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Eliquis by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GAMMAGARD LIQUID as an associated drug or biological on 29 records involving 8 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Gammagard Liquid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $295.84 | 15.5% | 11 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $257.69 | 13.5% | 9 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $233.72 | 12.2% | 13 | 2025 |
| United Therapeutics Corporation | Unresolved — no canonical attribution shown | $208.13 | 10.9% | 11 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $189.70 | 9.9% | 5 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $102.85 | 5.4% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $98.31 | 5.1% | 4 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $97.55 | 5.1% | 3 | 2025 |
| Shionogi Inc | Unresolved — no canonical attribution shown | $86.75 | 4.5% | 4 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $67.28 | 3.5% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $62.35 | 3.3% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $55.00 | 2.9% | 2 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $53.92 | 2.8% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $25.76 | 1.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $23.79 | 1.2% | 1 | 2025 |
| INOGEN, INC. | Unresolved — no canonical attribution shown | $20.26 | 1.1% | 1 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.40 | 1.0% | 1 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $15.35 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,734.66 | 77 |
| Education | $177.99 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $295.84 | 11 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $266.79 | 9 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $233.72 | 13 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $138.27 | 5 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $119.42 | 4 | 2025 |
Source payment records
|
|||||
| Tyvaso Normalized: tyvaso |
Drug | United Therapeutics Corporation | $109.26 | 7 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $102.85 | 4 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $98.31 | 4 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $97.55 | 3 | 2025 |
Source payment records
|
|||||
| Cresemba Normalized: cresemba |
Drug | Astellas Pharma US Inc | $90.70 | 4 | 2025 |
Source payment records
|
|||||
| Fetroja Normalized: fetroja |
Drug | Shionogi Inc | $86.75 | 4 | 2025 |
Source payment records
|
|||||
| Hillrom - Vest System Model 105 Home Care Normalized: hillrom vest system model 105 home care |
Device | Baxter Healthcare | $67.28 | 3 | 2025 |
Source payment records
|
|||||
| CUTAQUIG Normalized: cutaquig |
Biological | PFIZER INC. | $62.35 | 3 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $62.35 | 3 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $62.35 | 3 | 2025 |
Source payment records
|
|||||
| ARALAST Normalized: aralast |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $55.00 | 2 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $53.92 | 2 | 2025 |
Source payment records
|
|||||
| OPSYNVI Normalized: opsynvi |
Drug | Actelion Pharmaceuticals US, Inc. | $29.05 | 2 | 2025 |
Source payment records
|
|||||
| WINREVAIR Normalized: winrevair |
Biological | Merck Sharp & Dohme LLC | $25.76 | 1 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | AstraZeneca Pharmaceuticals LP | $23.79 | 1 | 2025 |
Source payment records
|
|||||
| INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH Normalized: inogen one g5 oxygen concentrator bluetooth |
Device | INOGEN, INC. | $20.26 | 1 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $18.40 | 1 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $15.35 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Cresemba cresemba |
2025 | Cresemba | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OFEV ofev |
2025 | Ofev | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Cresemba open payments reported associated product |
CMS Open Payments — General Payments 2800 supporting records · 1563 recipient NPIs · example record 1238560682 |
Cresemba · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | OFEV open payments reported associated product |
CMS Open Payments — General Payments 14236 supporting records · 6873 recipient NPIs · example record 1221811762 |
Ofev · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Grifols USA, LLC Exact reporting entity; no affiliate inference |
2025 | Gamunex-C open payments reported associated product |
CMS Open Payments — General Payments 3977 supporting records · 2134 recipient NPIs · example record 1249529381 |
Gamunex-C · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | PREVYMIS open payments reported associated product |
CMS Open Payments — General Payments 2265 supporting records · 1245 recipient NPIs · example record 1237992506 |
Prevymis · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
39 | 14 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | GAMMAGARD LIQUID open payments reported associated product |
CMS Open Payments — General Payments 29 supporting records · 8 recipient NPIs · example record 1223786557 |
Gammagard Liquid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Prednisone | Prednisone | 193 | 84 |
| Azithromycin | Azithromycin | 163 | 59 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 132 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 115 | 42 |
| Tacrolimus | Tacrolimus | 99 | 34 |
| Valganciclovir Hcl | Valganciclovir Hcl | 67 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 66 | 30 |
| Montelukast Sodium | Montelukast Sodium | 60 | 28 |
| Atovaquone | Atovaquone | 55 | 14 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 50 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 46 | 18 |
| Mycophenolic Acid | Mycophenolate Sodium | 45 | 16 |
| Gabapentin | Gabapentin | 42 | 18 |
| Eliquis | Apixaban | 39 | 14 |
| Furosemide | Furosemide | 38 | 17 |
| Ofev | Nintedanib Esylate | 36 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 35 | 17 |
| Amoxicillin | Amoxicillin | 34 | 22 |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 34 | 16 |
| Famotidine | Famotidine | 33 | 15 |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 33 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 28 | suppressed |
| Voriconazole | Voriconazole | 26 | 14 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 25 | suppressed |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 24 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 24 | suppressed |
| Sirolimus | Sirolimus | 24 | suppressed |
| Dapsone | Dapsone | 23 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 20 | suppressed |
| Envarsus Xr | Tacrolimus | 20 | suppressed |
| Amikacin Sulfate | Amikacin Sulfate | 19 | suppressed |
| Carvedilol | Carvedilol | 18 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Gammaked | Immune Globul G/Gly/Iga Avg 46 | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Prevymis | Letermovir | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 14 |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Posaconazole | Posaconazole | 15 | suppressed |
| Cresemba | Isavuconazonium Sulfate | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Astagraf Xl | Tacrolimus | 12 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 12 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 12 | suppressed |
| Methylprednisolone Sodium Succ | Methylprednisolone Sod Succ | 11 | suppressed |
| Potassium Chloride | Potassium Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,912.65 · 79 records | Actelion Pharmaceuticals US, Inc. | ACTHAR, ARALAST, Arikayce, CUTAQUIG, Cresemba, Fetroja, Hillrom - Vest System Model 105 Home Care, INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH, JASCAYD, NUCALA, OCTAGAM IMMUNE GLOBULIN (HUMAN), OFEV, OPSUMIT, OPSYNVI, PANZYGA, PURIFIED CORTROPHIN GEL, Prolastin-C Liquid, TEZSPIRE, Tyvaso, ULTOMIRIS, UPTRAVI, WINREVAIR, YUPELRI | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Cresemba play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error